3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Uterine Cervical Neoplasms
1
Skin Neoplasms
1
Neoplasm Metastasis
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinosarcoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Basal Cell Carcinoma of the Head and Neck
1
Interventions
pembrolizumab
24
Nivolumab
13
atezolizumab
7
Ipilimumab
6
Cyclophosphamide
6
fludarabine
5
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
aldesleukin
4
Interleukin-2
4
Biopsy
4
durvalumab
3
cemiplimab
3
Docetaxel
3
tislelizumab
2
osimertinib
2
fludarabine phosphate
2
enzalutamide
2
avelumab
2
X-Rays
2
Ritonavir
2
Radiotherapy
2
Observation
2
Methods
2
Immunoglobulin G
2
IFL protocol
2
Drug Therapy
2
zimberelimab
1
utomilumab
1
ulixertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Tissue Banks
×
Dermatologic
×
Clear all
NCT06349642
2026-03-12
ELEPHAS-04
Mayo Clinic
Recruiting
324 enrolled